Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH Translational Center To Study Cell-Based Toxicity Tests, Offer Industry Grants

Executive Summary

Toxicity testing is one area in which NIH Director Francis Collins expects the proposed National Center for Advancing Translational Science to help industry speed up drug development.

You may also be interested in...



NIH Repurposing Of Failed Compounds Could Begin Soon; NCATS Plans Pilots

The National Center for Advancing Translational Science soon may have an agreement with one or more firms to allow research to test abandoned compounds for new uses, NIH Deputy Director for Science, Outreach and Policy Kathy Hudson says. NIH has sought, and will continue to seek, industry input on where NCATS should put its efforts to speed translation of drugs from the bench to the market, she notes.

NIH Conflict Of Interest Reg Attracts Criticism From Transparency Advocates

A new upgrade to the National Institutes of Health’s1995 regulations overseeing researcher conflict of interests is intended as “an insurance plan” against potential trouble downstream, NIH Director Francis Collins says. But a key change in the final rule compared to an earlier proposal is attracting criticism from transparency advocates.

NIH Conflict Of Interest Reg Attracts Criticism From Transparency Advocates

A new upgrade to the National Institutes of Health’s1995 regulations overseeing researcher conflict of interests is intended as “an insurance plan” against potential trouble downstream, NIH Director Francis Collins says. But a key change in the final rule compared to an earlier proposal is attracting criticism from transparency advocates.

Related Content

Topics

UsernamePublicRestriction

Register

PS053559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel